Skip to main content

Advertisement

Table 1 Notable ongoing clinical trials in hematological malignancies

From: Checkpoint inhibitors in hematological malignancies

Malignancies Clinical trial # Phase Drug Study description Other name
Lymphoid neoplasm NCT02181738 2 Nivolumab Clinical activity of anti-PD-1 antibody in R/R CHL patients CheckMate 205
NCT01953692 2 Pembrolizumab Clinical activity of anti-PD-1 antibody in R/R CHL patients KEYNOTE-013
NCT02857426 2 Nivolumab Anti-PD-1 antibody in R/R PCNSL and PTL  
NCT02576990 2 Pembrolizumab Anti-PD-1 antibody in R/R PMBL KEYNOTE-170
NCT02220842 1 Atezolizumab Anti-PD-L1 antibody in combination with anti-CD20 antibody to R/R DLBCL or FL  
Plasma cell neoplasm NCT02036502 1 Pembrolizumab Clinical activity of anti-PD-1, lenalidomide and low-dose dexamethasone in R/R PCM patients shown KEYNOTE-023
NCT02903381 2 Nivolumab Lenalidomide, low-dose dexamethasone and anti-PD-1 antibody in smoldering PCM patients  
NCT01592370 1 Nivolumab Clinical activity of anti-PD-1 antibody in R/R PCM patients  
NCT02726581 3 Nivolumab Pomalidomide and dexamethasone with or without anti-PD-1 antibody in R/R PCM patients CheckMate 602
NCT02579863 3 Pembrolizumab Pomalidomide and dexamethasone with or without anti-PD-1 antibody in treatment-naïve PCM patients KEYNOTE-185
Myeloid neoplasms NCT02530463 2 Nivolumab HMA, ipilimumab, and anti-PD-1 antibody in MDS patients  
NCT01953692 1 Pembrolizumab Anti-PD-1 antibody in HMA-failed MDS patients  
NCT02845297 2 Pembrolizumab Anti-PD-1 with HMA in R/R AML patients  
NCT02275533 2 Nivolumab Anti-PD-1 antibody as post-remission therapy in AML patients  
NCT02117219 1 Durvalumab Anti-PD-L1 antibody, HMA, and tremelimumab in MDS patients  
  1. R/R relapsed refractory, PCNSL primary central nervous system lymphoma, PTL primary testicular lymphoma, PMBL primary mediastinal large B cell lymphoma, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, PCM plasma cell myeloma, HMA hypomethylating agent, MDS myelodysplastic syndrome, AML acute myeloid leukemia